BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. Cancer Shenzhen Forward Pharmaceuticals discovers new FGFR2 inhibitors Dec. 3, 2025 Shenzhen Forward Pharmaceuticals Co. Ltd. has described fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of stomach cancer and intrahepatic cholangiocarcinoma. BioWorld ScienceCancerPatents